Search
MN-246
go.drugbank.com/drugs/DB05981ExperimentalMN-246 is a novel ß3-adrenergic receptor agonist developed for the treatment of urinary incontinence by MediciNova Inc.
Zinc citrate
go.drugbank.com/drugs/DB11154ApprovedInvestigationalZinc citrate is a zinc salt of citric acid. It is available as dietary supplements as a treatment of zinc deficiency and source of zinc, which is an essential trace element. Zinc citrate demonstrates effective absorption following oral a...
Mixtures: High Potency Multivitamins & Minerals CapletsVilanterol
go.drugbank.com/drugs/DB09082ApprovedInvestigational[L46481,L44461,L44456] BREO ELLIPTA is the first vilanterol-containing product to be approved by the FDA in May 2013, followed by ANORO ELLIPTA in December 2013 and TRELEGY ELLIPTA in September 2020. … [A259961] Vilanterol was designed based on the salmeterol molecular scaffold, particularly as a antedrug analog of salmeterol modification by modifying the salmeterol molecule to create homochiral compounds
Apadamtase alfa
go.drugbank.com/drugs/DB15164ApprovedInvestigationalThrombotic thrombocytopenic purpura (TTP) is a rare blood clotting disorder characterized by thrombocytopenia, microangiopathic hemolytic anemia, and various degrees of organ damage. … [A262071] Apadamtase alfa, sold under the brand name Adzynma (ADAMTS13, recombinant-krhn), was approved by the FDA in November 2023 for use as an enzyme replacement therapy in patients with cTTP.
Cocaine
go.drugbank.com/drugs/DB00907ApprovedIllicitInvestigationalCocaine, like amphetamines, acts by multiple mechanisms on brain catecholaminergic neurons; the mechanism of its reinforcing effects is thought to involve inhibition of dopamine uptake.
Tirbanibulin
go.drugbank.com/drugs/DB06137ApprovedInvestigational[A225726] On December 14, 2020, tirbanibulin was approved by the FDA for the topical treatment of actinic keratosis on the face or scalp. It is marketed under the brand name Klisyri. … [L27806] Actinic keratosis is a chronic condition characterized by lesions, which can potentially transform into invasive squamous cell carcinoma with a risk of 1% over 10 years.
Halazepam
go.drugbank.com/drugs/DB00801ApprovedIllicitWithdrawn[A1212] This drug is no longer marketed in the United States, and was withdrawn by _Schering_, its manufacturer, in 2009.[L6226, L6229]
Ursodeoxycholic acid
go.drugbank.com/drugs/DB01586ApprovedInvestigational[A256272] UDCA works by replacing the hydrophobic or more toxic bile acids from the bile acid pool.[A256272] … [A256272] UDCA was first approved by the FDA in 1987 for dissolution of gallstones and for primary biliary cirrhosis in 1996.
Interferon gamma-1b
go.drugbank.com/drugs/DB00033ApprovedInvestigationalPurification of the product is achieved by conventional column chromatography. … The sequence displayed is a cDNA sequence which codes for human interferon gamma, as described by Gray et. al. and not specifically interferon gamma 1b.
Fluciclovine (18F)
go.drugbank.com/drugs/DB13146ApprovedInvestigational[A31384] The structure of fluciclovine allows it to be uptaken by the tumoral cells by its amino acid transporter without incorporating in the metabolism within the body. … [A31385] Fluciclovine was developed by Blue Earth Diagnostics, Ltd. and FDA approved in May 27, 2016.[L1049]